Are Senores Pharma. latest results good or bad?

Senores Pharmaceuticals has reported its financial results for the quarter ending June 2025, showcasing a significant increase in net sales, which reached Rs 19.82 crore, reflecting a growth of 100.5% compared to the average net sales of Rs 9.89 crore over the previous four quarters. This quarter also marked the highest profit after tax (PAT) recorded at Rs 2.70 crore, indicating a consistent upward trend over the last five quarters. Earnings per share (EPS) peaked at Rs 0.59, suggesting enhanced profitability for shareholders.
However, the company faced challenges in operational profitability, as indicated by a profit before tax (PBT) of Rs -4.80 crore, which represents a decline from the previous four-quarter average. Additionally, non-operating income made up a substantial 233.70% of PBT, raising questions about the sustainability of the company's business model.

In terms of quarterly performance, Senores Pharmaceuticals experienced a net sales growth of 30.61% compared to the previous quarter. The standalone net profit also showed a growth of 34.33% quarter-over-quarter. However, the operating profit margin, excluding other income, remained negative, and there was a notable decline in operating profit compared to the previous quarter.

Overall, while Senores Pharmaceuticals has demonstrated positive trends in sales and profit figures, it continues to navigate significant operational challenges. The company saw an adjustment in its evaluation based on these results.